CanSino Biologics Gets Registration Certificate for Meningitis Vaccine in Indonesia

MT NewswiresDec 30, 2024 06:28 ET

CanSino Biologics Expands Global Reach With Indonesian Vaccine Approval

TipRanksDec 30, 2024 04:09 ET

CANSINOBIO (06185.HK): Manhaixin has obtained the registration certificate from Indonesia.

On December 30, Gelonghui reported that CANSINOBIO (06185.HK) announced that its ACYW135 group meningococcal polysaccharide conjugate vaccine (CRM197 carrier) ("MCV4", trade name: Manhaixin) has obtained the registration certificate granted by the Indonesia Food and Drug Authority. The company's MCV4 is suitable for infants aged 3 months to 3 years (47 months), and vaccination with MCV4 can stimulate the body to produce immunity against the ACYW135 group Neisseria meningitidis for the prevention of epidemic meningitis caused by ACYW135 group Neisseria meningitidis, and is being developed domestically.

Gelonghui FinanceDec 30, 2024 03:52 ET

Express News | CanSino Biologics Inc - Menhycia Obtains Drug Registration Certificate in Indonesia

ReutersDec 30, 2024 03:50 ET

CanSino Biologics Inc. (688185.SH): MCV4 Manhaixin has obtained a registration certificate in Indonesia.

CanSino Biologics Inc. (688185.SH) announced that the company's ACYW135 group meningococcal polysaccharide conjugate vaccine (...)

Zhitong FinanceDec 30, 2024 03:32 ET

CanSino Biologics Inc. (688185.SH): The ACYW135 group meningococcal polysaccharide conjugate vaccine (CRM197 carrier) has obtained the registration certificate in Indonesia.

On December 30, Gelonghui reported that CanSino Biologics Inc. (688185.SH) announced that its ACYW135 group meningococcal polysaccharide conjugate vaccine (CRM197 carrier) (hereinafter referred to as "MCV4") has recently received the registration certificate granted by the Food and Drug Administration of Indonesia (Badan Pengawas Obat dan Makanan, Republik Indonesia, "BPOM").

Gelonghui FinanceDec 30, 2024 03:29 ET